Company / Cash & Equivalents
Compass Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$43.5M
FY2024
5-year range
$24.2M / $144.5M
FY2020-FY2024
Trend
+79.5%
vs FY2023
Sector context
#185 of 206
Health Care
What the data says
Among 206 Health Care companies, Compass Therapeutics, Inc. is in the bottom 10% for cash & equivalents. Cash & Equivalents returned to growth in FY2024 after 2 years of decline, reaching $43M.
Based on SEC 10-K filings.
$43M in FY2024 with a 5-year CAGR of +11.4%.
Improved from $35M to $43M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -33.0%
- 5-Year CAGR
- +11.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 206This company $43.5M Sector average $672.3M
▼
-93.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.4%, indicating consistent growth.
- In FY2024, cash & equivalents increased 79.5% year-over-year.
- Ranks #185 out of 206 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $43.5M | +79.5% |
| FY2023 | $24.2M | -30.7% |
| FY2022 | $34.9M | -75.8% |
| FY2021 | $144.5M | +207.0% |
| FY2020 | $47.1M | +86.0% |
| FY2019 | $25.3M | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026